Literature DB >> 9183340

Epidemiology and costs of acute hospital care for cerebrovascular disease in diabetic and nondiabetic populations.

C J Currie1, C L Morgan, L Gill, N C Stott, J R Peters.   

Abstract

BACKGROUND AND
PURPOSE: Little is known about the pattern of cerebrovascular disease (CVD) for diabetic and nondiabetic patients or about the cost of treatment for CVD in the United Kingdom. The purpose of this study was to extend previous work to describe the epidemiology and cost of acute care of CVD as a frequent comorbidity of diabetes in a UK population (408 000 people).
METHODS: Routine data describing inpatient care for a 4-year period were analyzed (financial years 1991/1992 to 1994/1995). These data had undergone record linkage to draw together records from the same patients. Cost estimates were determined by attributing a diagnosis-related group cost weight to each record. Mortality data from an overlapping period were supplied by the Office of Population Censuses and Surveys.
RESULTS: There were 11 196 CVD admissions (3.1% of all admissions). Of these, 7351 (66%) were primary diagnoses. These admissions were generated by 5358 patients (3904 primary diagnosis). For people with diabetes, the incidence rate was between 23 and 32.8 per 1000 per year compared with 2.4 to 3.3 per 1000 for the population as a whole, depending on the use of primary and subsidiary codes. The age-adjusted relative risk of stroke in diabetic men versus nondiabetic men was 3.70 (95% confidence interval, 3.53 to 3.88) and in women was 4.35 (95% confidence interval, 4.37 to 4.76). We describe other epidemiological relationships. The cost of CVD is between pounds 1.1 and pounds 1.6 million per 100 000 population-at least pounds 0.7 million per 100 000 for CVD alone. Approximately 15% of this value is related to diabetes, and an estimated 94% of this diabetes-related expenditure is potentially avoidable.
CONCLUSIONS: CVD represents a major source of expenditure for health services, and diabetes is confirmed as a major risk factor within this disease group. Differences between diabetic and nondiabetic inpatient patterns of CVD may reflect greater incidence of comorbidities in the former.

Entities:  

Mesh:

Year:  1997        PMID: 9183340     DOI: 10.1161/01.str.28.6.1142

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  6 in total

Review 1.  Use of routine healthcare data in safe and cost-effective drug use.

Authors:  C J Currie; T M MacDonald
Journal:  Drug Saf       Date:  2000-02       Impact factor: 5.606

2.  Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvar atrial fibrillation: a record linkage study in a large British population.

Authors:  M Jones; P McEwan; C Ll Morgan; J R Peters; J Goodfellow; C J Currie
Journal:  Heart       Date:  2005-04       Impact factor: 5.994

Review 3.  Diabetes and stroke: part one--risk factors and pathophysiology.

Authors:  Bantwal Suresh Baliga; Jesse Weinberger
Journal:  Curr Cardiol Rep       Date:  2006-02       Impact factor: 2.931

4.  Evaluation of survival and ischaemic and thromboembolic event rates in patients with non-valvar atrial fibrillation in the general population when treated and untreated with warfarin.

Authors:  C J Currie; M Jones; J Goodfellow; P McEwan; C L Morgan; C Emmas; J R Peters
Journal:  Heart       Date:  2005-05-09       Impact factor: 5.994

5.  Ultrasonic evaluation with second harmonic imaging and SonoVue in the assessment of cerebral perfusion in diabetic patients: a case-control study.

Authors:  Giuseppe Caruso; Giuseppe Salvaggio; Pietro Ragusa; Giuseppe Brancatelli; Roberto Lagalla
Journal:  Eur Radiol       Date:  2004-09-11       Impact factor: 5.315

6.  Prevalence of chronic complication among type 2 diabetics attending primary health care centers of Al Ahsa district of Saudi Arabia: a cross sectional survey.

Authors:  Ataur Rahman Khan; Zaki Naser Al Abdul Lateef; Shaheen Fatima; Sana Abdullah Ahmad Al Yousuf; Syed Zakaullah Khan Afghan; Salah Al Marghani
Journal:  Glob J Health Sci       Date:  2014-04-21
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.